Molecular cancer

Potential of engineered immune cells to treat solid tumors

Updated

Abstract

Adoptive cell immunotherapy using CARs specific for CD19 has shown remarkable responses in some patients with hematological malignancies.

  • CAR-T cell therapy has limited clinical efficacy in treating solid tumors.
  • Immunosuppression in solid tumors may arise from multiple mechanisms.
  • Strategies to enhance T cell effectiveness in solid tumors are being explored.
  • The review summarizes current approaches to overcome the immunosuppressive environment.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This is not applicable for this review. CONSENT FOR PUBLICATION: This is not applicable for this review. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free